Pathophysiology of Parkinson's disease

References

• AARSLAND, D., TANDBERG, E., LARSEN, J.P. & CUMMINGS, J.L. (1996). Frequency of dementia in Parkinson disease. Archives of Neurology, 53(6),538-542.
   Google Scholar
• AARSLAND, D., LARSEN, J.P., LIM, N.G., JANVIN, C., KARLSEN, K., TANDBERG, E. & CUMMINGS, J.L. (1999). Range of neuropsychiatric disturbances in patients with Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 67(4),492-496.
   PubMed Web of Science ®Google Scholar
• AGID, Y., AHLSKOG, E., ALBANESE, A., CALNE, D., CHASE, T., DEYEBENES, J., FACTOR, S., FAHN, S., GERSHANIK, O., GOETZ, C., KOLLER, W., KURTH, M., LANG, A., LEES, A., LEWITT, P., MARSDEN, D., MELAMED, E., MICHEL, P.P., MIZUNO, Y., OBESO, J., OERTEL, W., OLANOW, W., POEWE, W., POLLAK, P., TOLOSA, E., et al. (1999). Levodopa in the treatment of Parkinson’s disease: a consensus meeting. Movement Disorders, 14(6),911-913.
   PubMedGoogle Scholar
• BECKER, T., BECKER, G., SEUFERT, J., HOFMANN, E., LANGE, K.W., NAUMANN, M., LINDNER, A., REICHMANN, H., RIED-ERER, P., BECKMANN, H. & REINERS, K. (1997). Parkinson’s disease and depression: evidence for an alteration of the basal limbic system detectedby transcranial sonog-raphy. Journal of Neurology, Neurosurgery and Psychiatry, 63(5),590-596.
   Google Scholar
• BEJJANI, B., DAMIER, P., ARNULF, I., BONNET, A.M., VIDAI-LHET, M., DORMONT, D., PIDOUX, B., CORNU, P., MARSAULT, C. & AGID, Y. (1997).Pallidal stimulation for Parkinson’s disease.Two targets?. Neurology, 49(6),1564-1569.
   PubMed Web of Science ®Google Scholar
• BEJJANI, B.P., DAMIER, P., ARNULF, I., THIVARD, L., BONNET, A.M., DORMONT, D., CORNU, P., PIDOUX, B., SAMSON, Y. & AGID, Y. (1999).Transient acute depression induced by high-frequency deep-brain stimulation. New England Journal of Medicine, 340(19),1476-1480.
   PubMed Web of Science ®Google Scholar
• BERGMAN, H., RAZ, A., FEINGOLD, A., NINI, A., NELKEN, I., HANSEL, D., BEN-PAZI, H. & RECHES, A. (1998).Physiology of MPTP tremor.Movement Disorders, 13(Suppl 3),29-34.
   Google Scholar
• BEZARD, E., DOVERO, S., BIOULAC, B. & GROSS, C.E. (1997). Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neuroscience Letters, 234(1),47-50.
   Google Scholar
• BLANCHET, P.J., PAPA, S.M., METMAN, L.V., MOURADIAN, M.M. & CHASE, T.N. (1997). Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson’s disease. Neuroscience Biobehav-ioral Review, 21(4),447-453.
   PubMed Web of Science ®Google Scholar
• BRAVI, D., MOURADIAN, M.M., ROBERTS, J.W., DAVIS, T.L., SOHN, Y.H. & CHASE, T.N. (1994). Wearing-off ¯ uctua-tions in Parkinson’s disease: contribution of postsynaptic mechanisms. Annals of Neurology, 36(1),27-31.
   Google Scholar
• BROWN, R.G. & MARSDEN, C.D. (1988). Internal versus external cues and the control of attention in Parkinson’s disease. Brain, 111(2),323-345.
   PubMed Web of Science ®Google Scholar
• CASH, R., DENNIS, T., L’HEUREUX, R., RAISMAN, R., JAVOY-AGID, F. & SCATTON, B. (1987). Parkinson’s disease and dementia: norepinephrine and dopamine in locus ceru-leus. Neurology, 37(1),42-46.
   Google Scholar
• CHASE, T.N., OH, J.D. & BLANCHET, P.J. (1998). Neostriatal mechanisms in Parkinson’s disease. Neurology, 51(Suppl 2), S30 S35.
   Google Scholar
• CHONG, R.K., HORAK, F.B. & WOOLLACOTT, M.H. (2000). Parkinson’s disease impairs the ability to change set quickly. Journal of Neurological Science, 175(1),57-70.
   PubMed Web of Science ®Google Scholar
• CUMMINGS, J.L.(1992).Depression and Parkinson’s disease: a review. American Journal of Psychiatry, 149(4),443-454.
   Google Scholar
• CUMMINGS, J.L. (1995). Behavioral and psychiatric symptoms associated with Huntington’s disease.Advances in Neurology, 65, 179-186.
   PubMedGoogle Scholar
• CUMMINGS, J.L. & MASTERMAN, D.L. (1999). Depression in patients with Parkinson’s disease. International Journal of Geriatric Psychiatry, 14(9),711-718.
   PubMed Web of Science ®Google Scholar
• DAMIER, P., HIRSCH, E.C., AGID, Y. & GRAYBIEL, A.M. (1999). The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain, 122(8),1437-1448.
   PubMed Web of Science ®Google Scholar
• DELONG, M.R. (1990). Primate models of movement disorders of basal ganglia origin. Trends in Neuroscience, 13(7),281-285.
   PubMed Web of Science ®Google Scholar
• DEXTER, D.T., SIAN, J., ROSE, S., HINDMARSH, J.G., MANN, V.M., COOPER, J.M., WELLS, F.R., DANIEL, S.E., LEES, A.J., SCHAPIRA, A.H., et al. (1994). Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Annals of Neurology, 35(1),38-44.
   Google Scholar
• DOUDET, D., GROSS, C., LEBRUN-GRANDIE, P. & BIOULAC, B. (1985). MPTP primate model of Parkinson’s disease: a mechanographic and electromyographic study. B rain Research, 335(1),194-199.
   Google Scholar
• DUBOIS, B., DEFONTAINES, B., DEWEER, B., MALAPANI, C. & PILLON, B. (1995). Cognitive and behavioral changes in patients with focal lesions of the basal ganglia. Advances in Neurology, 65, 29-41.
   Google Scholar
• EIDELBERG, D., MOELLER, J.R., ISHIKAWA, T., DHAWAN, V., SPETSIERIS, P., SILBERSWEIG, D., STERN, E., WOODS, R.P., FAZZINI, E., DOGALI, M. & BERIC, A.(1996). Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson’s disease. Annals of Neurology, 39(4),450-459.
   Google Scholar
• ELIAS, J.W. & TRELAND, J.E.(1999). Executive function in Parkinson’s disease and subcortical disorders. Seminars in Clinical Neuropsychiatr y, 4(1),34-40.
   Google Scholar
• ELSWORTH, J.D., DEUTCH, A.Y., REDMOND, JR, D.E., SLADEK, JR., J.R. & ROTH, R.H.(1990). MPTP-induced parkin-sonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral eld of symptomatic and asymptomatic vervet monkeys. B rain Research, 513(2),320-324.
   Google Scholar
• FAHN, S., CLARENCE-SMITH, K.E. & CHASE, T.N.(1998). Parkinson’s disease: neurodegenerative mechanisms and neuroprotective interventions report of a workshop. Movement Disorders, 13(5),759-767.
   PubMedGoogle Scholar
• FEARNLEY, J.M. & LEES, A.J.(1991).Ageing and Parkinson’s disease: substantia nigra regional selectivity. B rain, 114(5),2283-2301.
   Google Scholar
• FIELDS, J.A. & TROSTER, A.I.(2000). Cognitive outcomes after deep brain stimulation for Parkinson’s disease: a review of initial studies and recommendations for future research. Brain Cognition, 42(2),268-293.
   Web of Science ®Google Scholar
• FILION, M., TREMBLAY, L. & BEDARD, P.J.(1988). Abnormal in¯ uences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. B rain Research, 444(1),165-176.
   Google Scholar
• FLASHMAN, L., MANDIR, A., HORNER, M. & FREIDES, D.(1991). Increasing interscorer reliability on theWisconsin Card Sorting Test (WCST) using clari ed scoring rules. Paper presented at the Internal Neuropsychology Society for the study of Brain Impariment, Queensland, Australia.
   Google Scholar
• FORNO, L.S.(1996).Neuropathology of Parkinson’s disease. Journal of Neuropathology Experiment Neurology, 55(3),259-272.
   Google Scholar
• FORNO, L.S., DELANNEY, L.E., IRWIN, I. & LANGSTON, J.W.(1993).Similarities and differences between MPTP-induced parkinsonsim and Parkinson’s disease. Neuropathologic considerations. Advances in Neurology, 60, 600-608.
   PubMedGoogle Scholar
• FORNO, L.S., LANGSTON, J.W., DELANNEY, L.E., IRWIN, I. & RICAURTE, G.A.(1986). Locus ceruleus lesions and eosi-nophilic inclusions in MPTP-treated monkeys. Annals of Neurology, 20(4),449-455.
   Google Scholar
• GERLACH, M. & RIEDERER, P.(1996). Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. Journal of Neural Transmission, 103(8-9), 987-1041.
   Google Scholar
• GILADI, N., TREVES, T.A., PALEACU, D., SHABTAI, H., ORLOV, Y., KANDINOV, B., SIMON, E.S. & KORCZYN, A.D.(2000). Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. Journal of Neural Transmission, 107(1),59-71.
   PubMed Web of Science ®Google Scholar
• GROSS, R.E., LOMBARDI, W.J., LANG, A.E., DUFF, J., HUTCHISON, W.D., SAINT-CYR, J.A., TASKER, R.R. & LOZANO, A.M.(1999). Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson’s disease. B rain, 122(3),405-416.
   Google Scholar
• HALLETT, M. & KHOSHBIN, S.(1980). A physiological mechanism of bradykinesia. B rain, 103(2),301-314.
   Google Scholar
• HARIK, S.I.(1992). MPTP toxicity and the `biochemical’ blood-brain barrier. NIDA Research Monograph, 120, 43-53.
   Google Scholar
• HORNYKIEWICZ, O.(1973). Parkinson’s disease: from brain homogenate to treatment. Federation Proceedings, 32(2),183-190.
   Google Scholar
• HORNYKIEWICZ, O.(1998). Biochemical aspects of Parkinson’s disease. Neurology, 51(Suppl 2), S2 S9.
   Google Scholar
• HSIEH, S., LEE, C.Y. & TAI, C.T.(1995).Set-shifting aptitude in Parkinson’s disease: external versus internal cues. Psychology Report, 77(1),339-349.
   Google Scholar
• HSIEH, S., CHUANG, Y.Y., HWANG, W.J. & PAI, M.C.(1998).A speci c shifting de cit in Parkinson’s disease: a reversal shift of consistent stimulus-response mappings. Perception of Motor Skills, 87(3),1107-1119.
   Google Scholar
• HSIEH, S., HWANG, W.J., TSAI, J.J. & TSAI, C.Y.(1996).Precued shifting of attention between cognitive sets in Parkinson patients. Psychology Report, 78(3),815-823.
   Google Scholar
• HUGDAHL, K. & WESTER, K.(2000).Neurocognitive correlates of stereotactic thalamotomy and thalamic stimulation in Parkinsonian patients. B rain Cognition, 42(2),231-252.
   Google Scholar
• HUGHES, T.A., ROSS, H.F., MUSA, S., BHATTACHERJEE, S., NATHAN, R.N., MINDHAM, R.H. & SPOKES, E.G.(2000).A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology, 54(8),1596-1602.
   Google Scholar
• HUTCHISON, W.D., LOZANO, A.M., TASKER, R.R., LANG, A.E. & DOSTROVSKY, J.O.(1997). Identi cation and characterization of neurons with tremor-frequency activity in human globus pallidus. Experimental Brain Research, 113(3),557-563.
   Google Scholar
• IRWIN, I., DELANNEY, L.E., FORNO, L.S., FINNEGAN, K.T., DI MONTE, D.A. & LANGSTON, J.W.(1990).The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Research, 531(1-2), 242-252.
   Google Scholar
• JAVITCH, J.A. & SNYDER, S.H.(1984). Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. European Journal of Pharmacology, 106(2),455-456.
   Google Scholar
• JAVITCH, J.A., UHL, G.R. & SNYDER, S.H.(1984). Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. Proceedings of the National Academy of Science USA, 81(14),4591-4595.
   Google Scholar
• JAVITCH, J.A., D’AMATO, R.J., STRITTMATTER, S.M. & SNYDER, S.H.(1985). Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proceedings of the National Academy of Science USA, 82(7),2173-2177.
   PubMed Web of Science ®Google Scholar
• JENNER, P.(1998).Oxidative mechanisms in nigral cell death in Parkinson’s disease. Movement Disorders, 13(Suppl 1), 24-34.
   Google Scholar
• KINEMUCHI, H., ARAI, Y. & TOYOSHIMA, Y.(1985). Participation of brain monoamine oxidase B form in the neuro-toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neuro-toxicity. Neuroscience Letters, 58(2),195-200.
   Google Scholar
• KISCHKA, U., MANDIR, A.S., GHIKA, J. & GROWDON, J.H.(1993). Electrophysiologic detection of extrapy-ramidal motor signs in Alzheimer’s disease. Neurology, 43(3),500-505.
   Google Scholar
• KITADA, T., ASAKAWA, S., HATTORI, N., MATSUMINE, H., YAMA-MURA, Y., MINOSHIMA, S., YOKOCHI, M., MIZUNO, Y. & SHIMIZU, N.(1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392(6676),605-608.
   Google Scholar
• KLIVENYI, P., ANDREASSEN, O.A., FERRANTE, R.J., DEDEOGLU, A., MUELLER, G., LANCELOT, E., BOGDANOV, M., ANDERSEN, J.K., JIANG, D. & BEAL, M.F.(2000). Mice de cient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Journal of Neuroscience, 20(1),1-7.
   Google Scholar
• KONITSIOTIS, S., BLANCHET, P.J., VERHAGEN, L., LAMERS, E. & CHASE, T.N.(2000). AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology, 54(8),1589-1595.
   PubMed Web of Science ®Google Scholar
• KRACK, P., POLLAK, P., LIMOUSIN, P., HOFFMANN, D., BENAZ-ZOUZ, A., LE BAS, J.F., KOUDSIE, A. & BENABID, A.L.(1998). Opposite motor effects of pallidal stimulation in Parkinson’s disease. Annals of Neurology, 43(2),180-192.
   PubMed Web of Science ®Google Scholar
• KUHN, W., MULLER, T., GROSSE, H. & ROMMELSPACHER, H.(1996). Elevated levels of harman and norharman in cerebrospinal ¯ uid of parkinsonian patients. Journal of Neural Transmission, 103(12),1435-1440.
   Google Scholar
• KUZUHARA, S., MORI, H., IZUMIYAMA, N., YOSHIMURA, M. & IHARA, Y.(1988). Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathologica, 75(4),345-353.
   Google Scholar
• LANGE, K.W., ROBBINS, T.W., MARSDEN, C.D., JAMES, M., OWEN, A.M. & PAUL, G.M.(1992).L-dopa withdrawal in Parkinson’s disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology, 107(2-3), 394-404.
   Google Scholar
• LANGSTON, J.W.(1996).The etiology of Parkinson’s disease with emphasis on the MPTP story.Neurology, 47(6, Suppl 3), S153 S160.
   Google Scholar
• LANGSTON, J.W., FORNO, L.S., TETRUD, J., REEVES, A.G., KAPLAN, J.A. & KARLUK, D.(1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Annals of Neurology, 46(4),598-605.
   PubMed Web of Science ®Google Scholar
• LE COUTEUR, D.G., MCLEAN, A.J., TAYLOR, M.C., WOODHAM, B.L. & BOARD, P.G.(1999). Pesticides and Parkinson’s disease. Biomedical Pharmacotherapy, 53(3),122-130.
   Google Scholar
• LEVIN, B.E., TOMER, R. & REY, G.J.(1992).Cognitive impairments in Parkinson’s disease. Neurologic Clinics, 10(2),471-485.
   Google Scholar
• LEVY, M.L., CUMMINGS, J.L., FAIRBANKS, L.A., MASTERMAN, D., MILLER, B.L., CRAIG, A.H., PAULSEN, J.S. & LITVAN, I.(1998). Apathy is not depression. Journal of Neuropsy-chiatry and Clinical Neurosciences, 10(3),314-319.
   PubMed Web of Science ®Google Scholar
• LIBERATORE, G.T., JACKSON-LEWIS, V., VUKOSAVIC, S., MANDIR, A.S., VILA, M., MCAULIFFE, W.G., DAWSON, V.L., DAWSON, T.M. & PRZEDBORSKI, S.(1999). Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.Natural Medicine, 5(12),1403-1409.
   PubMed Web of Science ®Google Scholar
• LIMOUSIN, P., GREENE, J., POLLAK, P., ROTHWELL, J., BENABID, A.L. & FRACKOWIAK, R.(1997). Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson’s disease. Annals of Neurology, 42(3),283-291.
   PubMed Web of Science ®Google Scholar
• LITVAN, I., PAULSEN, J.S., MEGA, M.S. & CUMMINGS, J.L.(1998).Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders [published erratum appears in Archives in Neurology, 55(12),1998,1591].Archives of Neurology, 55(10),1313-1319.
   Google Scholar
• LLOYD, K.G., MOHLER, H., HEITZ, P. & BARTHOLINI, G.(1975). Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and Parkinsonian patients. Journal of Neurochemistry, 25(6),789-795.
   Google Scholar
• LOMBARDI, W.J., GROSS, R.E., TREPANIER, L.L., LANG, A.E., LOZANO, A.M. & SAINT-CYR, J.A.(2000). Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson’s disease: support for the existence of cognitive circuits in the human pallidum. B rain, 123(4),746-758.
   Google Scholar
• MANDIR, A.S., PRZEDBORSKI, S., JACKSON-LEWIS, V., WANG, Z.Q., SIMBULAN-ROSENTHAL, C.M., SMULSON, M.E., HOFFMAN, B.E., GUASTELLA, D.B., DAWSON, V.L. & DAWSON, T.M.(1999). Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-inducedparkinsonism. Proceedings of the National Academy of Science USA, 96(10),5774-5779.
   Google Scholar
• MARSH, L.(2000). Neuropsychiatric aspects of Parkinson’s disease. Psychosomatics, 41(1),15-23.
   Google Scholar
• MAYBERG, H.S. & SOLOMON, D.H.(1995). Depression in Parkinson’s disease:a biochemical and organic viewpoint. Advances in Neurology, 65, 49-60.
   Google Scholar
• METMAN, L.V., KONITSIOTIS, S. & CHASE, T.N.(2000).Patho-physiology of motor response complications in Parkinson’s disease: hypotheses on the why, where, and what. Movement Disorders, 15(1),3-8.
   PubMed Web of Science ®Google Scholar
• MILLER, W.C. & DELONG, M.R.(1988).Parkinsonian symptomatology. An anatomical and physiological analysis. Annals NY Academy of Science, 515, 287-302.
   PubMedGoogle Scholar
• MONTINE, T.J., PICKLO, M.J., AMARNATH, V., WHETSELL, JR, W.O. & GRAHAM, D.G.(1997). Neurotoxicity of endogenous cysteinylcatechols. Experimental Neurology, 148(1),26-33.
   Google Scholar
• NWANZE, E., SOUVERBIE, F., JONSSON, G. & SUNDSTROM, E.(1995). Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity. Neuro-toxicology, 16(3),469-477.
   Google Scholar
• OWEN, A.M., DOYON, J., DAGHER, A., SADIKOT, A. & EVANS, A.C.(1998). Abnormal basal ganglia out¯ ow in Parkinson’s disease identi ed with PET. Implications for higher cortical functions. Brain, 121(5),949-965.
   PubMedGoogle Scholar
• PEREZ-OTANO, I., OSET, C., LUQUIN, M.R., HERRERO, M.T., OBESO, J.A. & DEL RIO, J.(1994).MPTP-induced parkin-sonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neuroscience Letters, 175(1-2), 121-125.
   Google Scholar
• PIFL, C., SCHINGNITZ, G. & HORNYKIEWICZ, O.(1988). The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson’s disease. Neuroscience Letters, 92(2),228-233.
   Google Scholar
• POLYMEROPOULOS, M.H., LAVEDAN, C., LEROY, E., IDE, S.E., DEHEJIA, A., DUTRA, A., PIKE, B., ROOT, H., RUBENSTEIN, J., BOYER, R., STENROOS, E.S., CHANDRASEKHARAPPA, S., ATHANASSIADOU, A., PAPAPETROPOULOS, T., JOHNSON, W.G., LAZZARINI, A.M., DUVOISIN, R.C., DI IORIO, G., GOLBE, L.I. & NUSSBAUM, R.L.(1997). Mutation in the alpha synuclein gene identi ed in families with Parkinson’s disease. Science, 276(5321),2045-2047.
   Google Scholar
• PRAAMSTRA, P., COOLS, A.R., STEGEMAN, D.F. & HORSTINK, M.W.(1996). Movement-related potential measures of different modes of movement selection in Parkinson’s disease. Journal of Neurology Science, 140(1-2), 67-74.
   Google Scholar
• PRAAMSTRA, P., PLAT, E.M., MEYER, A.S. & HORSTINK, M.W.(1999). Motor cortex activation in Parkinson’s disease: dissociation of electrocortical and peripheral measures of response generation. Movement Disorders, 14(5),790-799.
   Google Scholar
• PRZEDBORSKI, S., JACKSON-LEWIS, V., YOKOYAMA, R., SHIBATA, T., DAWSON, V.L. & DAWSON, T.M.(1996).Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-ridine (MPTP)-induced dopaminergic neurotoxicity. Proceedings of the National Academy of Science USA, 93(10),4565-4571.
   PubMed Web of Science ®Google Scholar
• RANSOM, B.R., KUNIS, D.M., IRWIN, I. & LANGSTON, J.W.(1987).Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neuroscience Letters, 75(3),323-328.
   Google Scholar
• RASKIN, S.A., BOROD, J.C. & TWEEDY, J.R.(1992).Set-shifting and spatial orientation in patients with Parkinson’s disease. Journal of Clinical Experimental Neuropsychology, 14(5),801-821.
   PubMed Web of Science ®Google Scholar
• RAZ, A., FEINGOLD, A., ZELANSKAYA, V., VAADIA, E. & BERGMAN, H.(1996). Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates. Journal of Neurophysiology, 76(3),2083-2088.
   PubMed Web of Science ®Google Scholar
• RIEDERER, P. & WUKETICH, S.(1976).Time course of nigros-triatal degeneration in parkinson’s disease. A detailed study of in¯ uential factors in human brain amine analysis. Journal of NeuralTransmission, 38(3-4), 277-301.
   Google Scholar
• RINNE, J.O., PORTIN, R., RUOTTINEN, H., NURMI, E., BERGMAN, J., HAAPARANTA, M. & SOLIN, O.(2000).Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]¯ uorodopa positron emission tomo-graphic study. Archives of Neurology, 57(4),470-475.
   PubMed Web of Science ®Google Scholar
• RITZ, B. & YU, F.(2000). Parkinson’s disease mortality and pesticide exposure in California 1984-1994.International Journal of Epidemiology, 29(2),323-329.
   PubMed Web of Science ®Google Scholar
• ROBERTSON, C. & FLOWERS, K.A.(1990). Motor set in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 53(7),583-592.
   Google Scholar
• RODRIGUEZ, M.C., GURIDI, O.J., ALVAREZ, L., MEWES, K., MACIAS, R., VITEK, J., DELONG, M.R. & OBESO, J.A.(1998). The subthalamic nucleus and tremor in Parkinson’s disease. Movement Disorders, 13(Suppl 3), 111-118.
   Google Scholar
• SAMUEL, M., CEBALLOS-BAUMANN, A.O., TURJANSKI, N., BOECKER, H., GOROSPE, A., LINAZASORO, G., HOLMES, A.P., DELONG, M.R., VITEK, J.L., THOMAS, D.G., QUINN, N.P., OBESO, J.A. & BROOKS, D.J.(1997). Pallidotomy in Parkinson’s disease increases supplementary motor area and prefrontal activation during performance of volitional movements an H2(15)O PET study. B rain, 120(8),1301-1313.
   Google Scholar
• SCATTON, B., JAVOY-AGID, F., ROUQUIER, L., DUBOIS, B. & AGID, Y.(1983). Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. B rain Research, 275(2),321-328.
   Google Scholar
• SCHAPIRA, A.H.(1993). Mitochondrial complex I de ciency in Parkinson’s disease.Advances in Neurology, 60, 288-291.
   Google Scholar
• SCHAPIRA, A.H.(1999). Mitochondrial involvement in Parkinson’s disease, Huntington’s disease, hereditary spastic paraplegia and Friedreich’s ataxia. Biochimica Biophysica Acta, 1410(2),159-170.
   Google Scholar
• SCHAPIRA, A.H., COOPER, J.M., DEXTER, D., CLARK, J.B., JENNER, P. & MARSDEN, C.D.(1990). Mitochondrial complex I de ciency in Parkinson’s disease. Journal of Neurochemistry, 54(3),823-827.
   PubMed Web of Science ®Google Scholar
• SCHAPIRA, A.H., COOPER, J.M., DEXTER, D., JENNER, P., CLARK, J.B. & MARSDEN, C.D.(1989). Mitochondrial complex I de ciency in Parkinson’s disease [letter].Lancet, 1(8649), 1269.
   Google Scholar
• SCHIFFER, R.B.(1999). Anxiety disorders in Parkinson’s disease: insights into the neurobiology of neurosis [editorial]. Journal of Psychosomatic Research, 47(6),505-508.
   Google Scholar
• SCHNEIDER, J.S. & POPE-COLEMAN, A.(1995). Cognitive de cits precede motor de cits in a slowly progressing model of parkinsonism in the monkey. Neurodegenera-tion, 4(3),245-255.
   Google Scholar
• SCHULZ, J.B., MATTHEWS, R.T., MUQIT, M.M., BROWNE, S.E. & BEAL, M.F.(1995). Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice.Journal of Neurochemistry, 64(2),936-939.
   Google Scholar
• SCOTT, R., GREGORY, R., HINES, N., CARROLL, C., HYMAN, N., PAPANASSTASIOU, V., LEATHER, C., ROWE, J., SILBURN, P. & AZIZ, T.(1998). Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson’s disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures. B rain, 121(4),659-675.
   Google Scholar
• SHIBA, M., BOWER, J.H., MARAGANORE, D.M., MCDONNELL, S.K., PETERSON, B.J., AHLSKOG, J.E., SCHAID, D.J. & ROCCA, W.A.(2000). Anxiety disorders and depressive disorders preceding Parkinson’s disease:a case-control study. Movement Disorders, 15(4),669-677.
   PubMed Web of Science ®Google Scholar
• SIAN, J., DEXTER, D.T., LEES, A.J., DANIEL, S., JENNER, P. & MARSDEN, C.D.(1994). Glutathione-related enzymes in brain in Parkinson’s disease. Annals of Neurology, 36(3),356-361.
   Google Scholar
• SIMPSON, J.A. & KHURAIBET, A.J.(1987). Readiness potential of cortical area 6 preceding self paced movement in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 50(9),1184-1191.
   Google Scholar
• SINGH, A., BLACK, S.E., HERRMANN, N., LEIBOVITCH, F.S., EBERT, P.L., LAWRENCE, J. & SZALAI, J.P.(2000). Functional and neuroanatomic correlations in poststroke depression: the Sunnybrook Stroke Study. Stroke, 31(3),637-644.
   PubMed Web of Science ®Google Scholar
• SMITH, T.S., PARKER, JR, W.D. & BENNETT, JR, J.P.(1994).L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreport, 5(8),1009-1011.
   Google Scholar
• SNOW, B.J., VINGERHOETS, F.J., LANGSTON, J.W., TETRUD, J.W., SOSSI, V. & CALNE, D.B.(2000). Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 68(3),313-316.
   Google Scholar
• SNYDER, S.H. & D’AMATO, R.J.(1986). MPTP: a neurotoxin relevantto the pathophysiology of Parkinson’s disease. The 1985 George C.Cotzias lecture.Neurology, 36(2),250-258.
   Google Scholar
• SPILLANTINI, M.G., CROWTHER, R.A., JAKES, R., HASEGAWA, M. & GOEDERT, M.(1998). alpha-Synuclein in lamen-tous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies.Proceedings of the National Academy of Science USA, 95(11),6469-6473.
   PubMed Web of Science ®Google Scholar
• STEPHENSON, J.(2000). Exposure to home pesticides linked to Parkinson disease. Journal of the American Medical Association, 283(23),3055-3056.
   Google Scholar
• STERN, Y., TETRUD, J.W., MARTIN, W.R., KUTNER, S.J. & LANG-STON, J.W.(1990). Cognitive change following MPTP exposure. Neurology, 40(2),261-264.
   Google Scholar
• TAKEDA, A., MALLORY, M., SUNDSMO, M., HONER, W., HANSEN, L. & MASLIAH, E.(1998). Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. American Journal of Pathology, 152(2),367-372.
   PubMed Web of Science ®Google Scholar
• TILLER, J.W.(1992). Post-stroke depression. Psychopharma-cology (Berlin), 106(Suppl), S130 S133.
   Google Scholar
• TREPANIER, L.L., SAINT-CYR, J.A., LOZANO, A.M. & LANG, A.E.(1998).Neuropsychological consequences of poster-oventral pallidotomy for the treatment of Parkinson’s disease. Neurology, 51(1),207-215.
   Google Scholar
• TREPANIER, L.L., KUMAR, R., LOZANO, A.M., LANG, A.E. & SAINT-CYR, J.A.(2000).Neuropsychological outcomeof GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson’s disease. B rain Cognition, 42(3),324-347.
   PubMed Web of Science ®Google Scholar
• TROSTER, A.I., FIELDS, J.A., WILKINSON, S.B., PAHWA, R., MIYAWAKI, E., LYONS, K.E. & KOLLER, W.C.(1997). Unilateral pallidal stimulation for Parkinson’s disease: neurobehavioral functioning before and 3 months after electrode implantation. Neurology, 49(4),1078-1083.
   PubMed Web of Science ®Google Scholar
• TURNER, B.H., WILSON, J.S., MCKENZIE, J.C. & RICHTAND, N.(1988). MPTP produces a pattern of nigrostriatal degeneration which coincides with the mosaic organization of the caudate nucleus.B rain Research, 473(1),60-64.
   Google Scholar
• VARASTET, M., RICHE, D., MAZIERE, M. & HANTRAYE, P.(1994). Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson’s disease. Neuroscience, 63(1),47-56.
   PubMed Web of Science ®Google Scholar
• WAKABAYASHI, K., MATSUMOTO, K., TAKAYAMA, K., YOSHI-MOTO, M. & TAKAHASHI, H.(1997). NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson’s disease. Neuroscience Letters, 239(1),45-48.
   PubMed Web of Science ®Google Scholar
• WATTS, R.L. & MANDIR, A.S.(1992). The role of motor cortex in the pathophysiology of voluntary movement de cits associated with parkinsonism. Neurologic Clinics, 10(2),451-469.
   Google Scholar
• WATTS, R.L., MANDIR, A.S. & BAKAY, R.A.(1995).Intrastriatal cografts of autologous adrenal medulla and sural nerve in MPTP-induced parkinsonian macaques: behavioral and anatomical assessment. CellTransplant, 4(1),27-38.
   Google Scholar
• WATTS, R.L., MANDIR, A.S., AHN, K.J., JUNCOS, J.L., ZAKERS, G.O. & FREEMAN, A.(1991). Electrophysiologic analysis of early Parkinson’s disease. Geriatrics, 46(Suppl 1), 31-36.
   Google Scholar
• WATTS, R.L., BAKAY, R.A., HERRING, C.J., SWEENEY, K.M., COLBASSANI, H.J., MANDIR, A., BYRD, L.D. & IUVONE, P.M.(1990). Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys. Progress in Brain Research, 82, 581-591.
   Google Scholar
• WEISS, B.(2000). Vulnerability to pesticide neurotoxicity is a lifetime issue. Neurotoxicology, 21(1-2), 67-73.
   Google Scholar
• WICHMANN, T. & DELONG, M.R.(1998). Models of basal ganglia function and pathophysiology of movement disorders. Neurosurgery Clinics of North America, 9(2),223-236.
   PubMed Web of Science ®Google Scholar